Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506829 · ClinicalTrials.gov registry record · NA
Financial Incentives for Smoking Treatment
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT02506829: Completed NA study, sponsored by NYU Langone Health.
NCT02506829 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02506829, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
The investigators plan to compare the impact of two approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life among a diverse population of patients at the Manhattan campus of the VA New York Harbor Healthcare System, which serves a critical safety-net role for urban veterans. During hospitalization, all smokers will receive usual care. Patients will be randomized to one of two arms: financial incentives plus usual care vs. usual care alone, which includes referral to the state Quitline. All patients enrolled in the study will be offered nicotine replacement therapy. The investigators will conduct follow-up assessments at 2 weeks, 2 months, 6 months and 12 months after discharge. The primary study outcome is smoking abstinence at 6-month follow-up, verified by salivary/urinary cotinine.
Primary Outcome
Assessed by self-report questionnaire, and biochemically verified by salivary cotinine
Interventions
- BEHAVIORAL Financial incentives
- BEHAVIORAL Smoking cessation counseling (Quitline)
- BEHAVIORAL Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-05-20 |
| Phase | NA |
What the finished NCT02506829 record still lists
NCT02506829 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Financial incentives is the first listed.
NCT02506829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02506829 about?
NCT02506829 is a clinical study titled "Financial Incentives for Smoking Treatment". The investigators plan to compare the impact of two approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life among a diverse population of patients at the Manhattan campus of the VA New York Harbor Healthcare System, which serves a critical safety-n...
What is the current status of trial NCT02506829?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2015-07. Estimated completion is 2019-05-20.
What interventions are being tested in trial NCT02506829?
The interventions under investigation include: Financial incentives (BEHAVIORAL), Smoking cessation counseling (Quitline) (BEHAVIORAL), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02506829?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02506829's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia